The biotech mergers and acquisitions market faces significant headwinds in the first half of 2025. These challenges include frozen capital markets, regulatory uncertainty at the Food and Drug Administration (FDA) and...more
4/22/2025
/ Acquisitions ,
Biotechnology ,
Capital Markets ,
Department of Health and Human Services (HHS) ,
Financial Distress ,
Food and Drug Administration (FDA) ,
Mergers ,
Pharmaceutical Industry ,
Regulatory Requirements ,
Reverse Mergers ,
Shareholder Activism